CXCR7-agonist counters the generation of arachidonic acid (AA), 12-hydroxyheptadecatrenoic acid (12-HHT), TxA2, 12-HETE, LPIs, and DGs from thrombin activated platelets of healthy subjects and CAD patients ex vivo. This evidence concerns the gene ACKR3 and coronary artery disorder.